Slow-replicating leukemia cells represent a leukemia stem cell population with high cell-surface CD74 expression
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Persistent leukemia stem cells (LSCs) drive chemotherapy resistance. This study identifies slow-cycling LSCs using PKH dye and finds CD74 is a potential surface marker for targeting these resistant cells.
Area Of Science
- Hematology
- Cancer Biology
- Stem Cell Research
Background
- Quiescent leukemia stem cells (LSCs) persist post-treatment, leading to chemotherapy resistance and poor leukemia prognosis.
- Identifying these quiescent LSCs is crucial for developing effective eradication strategies.
Purpose Of The Study
- To identify and characterize quiescent leukemia stem cells (LSCs) in leukemia models.
- To investigate the role of CD74 as a potential surface marker for LSCs.
Main Methods
- Utilized PKH26 cell-tracing dye to identify label-retaining, slow-cycling leukemia cells in vivo.
- Analyzed cell cycle phase (G0), colony formation, leukemia initiation potential, and chemo-resistance of PKH-retaining cells.
- Examined gene expression and cell surface marker profiles, focusing on CD74, in leukemia cells.
Main Results
- Identified a slow-cycling, label-retaining leukemia cell population with enhanced colony formation and leukemia initiation potential.
- PKH-retaining cells exhibited higher chemo-resistance and preferential localization to the endosteal bone marrow.
- HLA class II histocompatibility antigen gamma chain (CD74) was highly expressed in these LSCs and on CD34+ human leukemia cells.
- CD74+ leukemia cells demonstrated increased stemness properties compared to CD74- cells.
Conclusions
- The identified slow-cycling, PKH-retaining cells represent a leukemia stem cell (LSC) population.
- CD74 is a promising surface marker for LSCs, offering a potential target for leukemia therapy.
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
Related Concept Videos
Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
The hematopoietic stem cells or HSCs are multipotent, meaning they can differentiate and give rise to all blood and immune cells. HSCs are maintained in the quiescent stage until an external stimulus initiates their differentiation. The multipotent HSCs exist as two heterogeneous populations, long-term repopulating cells (LTRC) and short-term repopulating cells (STRC). The two HSC populations have different surface markers or receptors and are classified based on quiescence and long-term...